Latest chemotherapy Stories
Data Presented at the 19th Annual Society for Neuro-Oncology Meeting Demonstrate VAL-083 Superiority to Temozolomide in Key Preclinical Models VANCOUVER, British Columbia, MENLO PARK, Calif.,
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
A few treatment options and tips for one dealing with lung cancer. (PRWEB) November 12, 2014 For such a serious medical condition, the symptoms warning
Research shows promise for increasing effectiveness of chemo and reduction of metastasis DALLAS, Nov.
Insilico Medicine, Inc and Champions Oncology announce research collaboration on drug discovery and in silico drug efficacy evaluation in oncology Baltimore,
CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy INDIANAPOLIS, Nov.
UC Davis researchers link increased body fat and lethal drug reactions in mice SACRAMENTO, Calif.
The Mesothelioma Applied Research Foundation is optimistic about results reported by AduroBioTech, Inc.
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
- totally perplexed and mixed up.